In the last trading session, 4.23 million Omega Therapeutics Inc (NASDAQ:OMGA) shares changed hands as the company’s beta touched 1.73. With the company’s per share price at $0.14 changed hands at -$0.02 or -10.82% during last session, the market valuation stood at $7.89M. OMGA’s last price was a discount, traded about -3085.71% off its 52-week high of $4.46. The share price had its 52-week low at $0.10, which suggests the last value was 28.57% up since then.
Analysts gave the Omega Therapeutics Inc (OMGA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended OMGA as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Omega Therapeutics Inc’s EPS for the current quarter is expected to be -0.28.
Omega Therapeutics Inc (NASDAQ:OMGA) trade information
Instantly OMGA was in red as seen at the end of in last trading. With action -37.95%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -80.87%, with the 5-day performance at -37.95% in the red. However, in the 30-day time frame, Omega Therapeutics Inc (NASDAQ:OMGA) is -70.08% down.
The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need an upside of 98.44% from its current market value. According to analyst projections, OMGA’s forecast low is 7 with 11 as the target high. To hit the forecast high, the stock’s price needs a -7757.14% plunge from its current level, while the stock would need to soar -4900.0% for it to hit the projected low.
Omega Therapeutics Inc (OMGA) estimates and forecasts
Year-over-year growth is forecast to reach 100.19% up from the last financial year.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 850k. 1 analysts are of the opinion that Omega Therapeutics Inc’s revenue for the current quarter will be 850k. The company’s revenue for the corresponding quarters a year ago was 989k and 2.36M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -14.05%. The estimates for the next quarter sales put growth at -63.98%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -48.08%. The 2025 estimates are for Omega Therapeutics Inc earnings to decrease by -26.67%.
OMGA Dividends
Omega Therapeutics Inc is expected to release its next quarterly earnings report in March.
FMR LLC holds the second largest percentage of outstanding shares, with 11.3181% or 6.24 million shares worth $12.92 million as of 2024-06-30.
